Vicore Pharma Holding AB

Vicore Pharma Holding AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03.VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

New positive study results on diabetic nephropathy with Vicore Pharma's candidate drug C21

Wed, May 03, 2017 15:00 CET

C21 combined with an angiotensin receptor blocker (ARB) provides improved treatment effect in type 2 diabetes animal model. Vicore Pharma AB (ticker: VICO), a Swedish biotech company developing drugs that act through the AT2 receptor in the renin angiotensin system, today announced positive results from a preclinical study in which researchers in India have studied the effects of C21 in combination with an ARB on mechanisms of diabetic nephropathy in a type 2 diabetes animal model.The results were published on May 1, 2017 in the scientific journal Biochemical and Biophysical Research

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

New positive study results on diabetic nephropathy with Vicore Pharma's candidate drug C21

Media